United States Department of Veterans Affairs
Research Advisory Committee on Gulf War Veterans' Illnesses

Research Update - April 2009

The following journal articles were distributed for review in April 2009.  You can access the article's abstract by copying the paper title and pasting it into the search bar of the PubMed website, linked here. 

Recently Published Scientific Research

Gulf War Specific Articles

a. Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. (Haley RW, Spence JS, Carmack PS, Gunst RF, Schucany WR, Petty F, Devous MD Sr, Bonte FJ, Trivedi MH. Psychiatry Res.2009 Mar 31;171(3):207-20.)   

b. Clinical aspects of ALS in Gulf War veterans. (Kasarskis EJ, Lindquist JH, Coffman CJ, Grambow SC, Feussner JR, Allen KD, Oddone EZ, Kamins KA, Horner RD; ALS Gulf War Clinical Review Team. Amyotroph Lateral Scler. 2009 Feb;10(1):35-41.)

c. Surveillance results of depleted uranium-exposed Gulf War I veterans: sixteen years of follow-up. (McDiarmid MA, Engelhardt SM, Dorsey CD, Oliver M, Gucer P, Wilson PD, Kane R, Cernich A, Kaup B, Anderson L, Hoover D, Brown L, Albertini R, Gudi R, Squibb KS. J Toxicol Environ Health A. 2009;72(1):14-29.)  

d. Impaired immune function in Gulf War Illness. (Whistler T, Fletcher MA, Lonergan W, Zeng XR, Lin JM, Laperriere A, Vernon SD, Klimas NG. BMC Med Genomics. 2009 Mar 5;2:12.)

e. Acetylcholinesterase inhibitors and Gulf War illnesses. (Golomb BA. Proc Natl Acad Sci USA. 2008 Mar 18;105(11):4295-300.)

f. Acetylcholinesterase inhibition and Gulf War illnesses: conclusions are not supported by independent reviews of the same evidence. (Blazer D, Gray GC, Hotopf M, Macfarlane G, Sim M, Smith TC, Wessely S. Proc Natl Acad Sci USA. 2008 Apr 29;105(17):E20.)

g. Reply to Blazer et al.: flawed challenges to "Acetylcholinesterase inhibitors and Gulf War illnesses". (Golomb BA. Proc Natl Acad Sci USA. 2008 Aug 19;105(33):E53.)


Other Relevant Research

Papers Published in 2009

a. Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants.(Dickson A, Toft A, O'Carroll RE. Psychol Med. 2009 Jan 15:1-10. [Epub ahead of print])

b. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. (Gong M, Garige M, Varatharajalu R, Marmillot P, Gottipatti C, Leckey LC, Lakshman RM. Biochem Biophys Res Commun. 2009 Feb 20;379(4):1001-4.)

c. Chronic fatigue syndrome and mitochondrial dysfunction. (Myhill S, Booth NE , Howard JM. Int J Clin Exp Med. 2009; 2(1):1-16)

d. Neuroinflammatory changes increase the impact of stressors on neuronal function. (Piazza A, Lynch MA. Biochem Soc Trans. 2009 Feb;37(Pt 1):303-7.)

e. The possible use of oximes as antidotal therapy in organophosphate-induced brain damage. (Shrot S, Markel G, Dushnitsky T, Krivoy A. Neurotoxicology. 2009 Mar;30(2):167-73.)

f. Current opinion on the science of organophosphate pesticides and toxic stress: a systematic review. (Soltaninejad K, Abdollahi M. Med Sci Monit. 2009 Mar;15(3):RA75-90.)

Papers Published in 2008

g. Is it too soon for mesenchymal stem cell trials in people with ALS? (Badayan I, Cudkowicz ME. Amyotroph Lateral Scler. 2008 Dec;9(6):321-2.)

h. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. (Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2304-19.)

i. Neuroendocrine and immune network re-modeling in chronic fatigue syndrome: an exploratory analysis. (Fuite J, Vernon SD , Broderick G. Genomics. 2008 Dec;92(6):393-9.)

j. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. (Jang S, Kelley KW, Johnson RW. Proc Natl Acad Sci USA . 2008 May 27;105(21):7534-9.)

k. Repeated stress in combination with pyridostigmine Part I: long-term behavioural consequences. (Lamproglou I, Barbier L, Diserbo M, Fauvelle F, Fauquette W, Amourette C. Behav Brain Res. 2009 Feb 11;197(2):301-10. Epub 2008 Aug 29.)

l. Repeated stress in combination with pyridostigmine Part II: changes in cerebral gene expression. (Barbier L, Diserbo M, Lamproglou I, Amourette C, Peinnequin A, Fauquette W. Behav Brain Res. 2009 Feb 11;197(2):292-300. Epub 2008 Aug 29.)

m. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. (Levite M. Curr Opin Pharmacol. 2008 Aug;8(4):460-71.)

n. Stress-induced neuroinflammation: mechanisms and new pharmacological targets. (Munhoz CD, García-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC. Braz J Med Biol Res. 2008 Dec;41(12):1037-46.)

o. Chronic fatigue syndrome with autoantibodies--the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. (Nancy AL, Shoenfeld Y. Autoimmun Rev. 2008 Oct;8(1):52-5.)

p. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. (Offner H, Sinha S, Wang C, Burrows GG, Vandenbark AA. Rev Neurosci. 2008;19(4-5):327-39.)

q. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. (Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, Dang Y, Zhang J, Jiang H, Penner R, Liu JO. PLoS ONE. 2008;3(12):e4009.)

r. Peripheral mechanisms of pain and analgesia. (Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, Vanderah TW, Spencer RH. Brain Res Rev. 2008 Dec 31. [Epub ahead of print])

s. Right anterior cingulate cortical volume covaries with respiratory sinus arrhythmia magnitude in combat veterans.(Woodward SH, et al. J Rehabil Res Dev. 2008;45(3):451-63.)